Theme: Ensure safer drugs to the healthcare community

Global Pharmacovigilance 2016

Renowned Speakers

Global Pharmacovigilance 2016

Conference Series LLC organizing splendorous Pharmaceutical conferences welcomes you to attend the 5th Global Pharmacovigilance Summit to be held during April 28-29, 2016 in Dubai,UAE focuses on the advancements in pharmacovigilance and risk management.

 
The field of Pharmacovigilance is growing by and large, its development is making high impact in field of Pharmaceuticals and medical sciences. 5th Global Pharmacovigilance Summit focusses on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence. Main theme of 5th Global Pharmacovigilance Summit is “Ensuring Safer Drugs to the Healthcare Community”.
 

Track-1: Drug Safety:

Drug Safety or Pharmacovigilance (PV or PhV), is the  study of Pharmacology  related to the data collection, assessment, detection,  monitoring, and prevention of adverse effects with drug products. In this Track we will discuss about  Drug safety awith its importance in various fields as Training, softwares etc. & other topics which are  discussed in Pharmacovigilance Conferences

Related Conferences:

International Conference and Exhibition on Advances in HPLC and Chromatography Techniques ,March 17-18, 2016, London, UK; Asia Pacific Drug Formulation & Bioavailability Congress, Beijing, China, June 06-08, 2016; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics , June 09-10, 2016, Dallas, USA ; 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 12-14, 2016, San Atonio, USA;2nd International Conference and Expo on Drug Discovery and Designing, October 24-26, 2016, Istanbul, Turkey; 6th Annual Pharmacovigilance and Risk Management Strategies Forum; SCT 37th Annual Meeting (2016); Conference on Pharmacology and Toxicology Research; Pharmacovigilance Conferences and Risk Management Strategies 2016

Track-2: Adverse Drug Reactions:

Adverse drug reaction (ADR) can be defined as a damage caused by taking a medication. Most of the adverse drug reactions represent an enhancement  of the drug's therapeutic effects. There are various types of Adverse Drug Reactions and its effect on the body. Proper assessment and reporting of adverse drug reactions is important for drug safety systems. In this track we will focus on  Expected and un-expected drug reactions and its reporting. Even drug product manufacturers, professionals, and consumers can report Post marketing reports on adverse effects & other topics which are  discussed in Pharmacovigilance Conferences

Related Conferences:

2nd International Conference on Clinical Trials , August 22-24, 2016, Philadelphia, USA; 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 12-14, 2016, San Atonio, USA; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics , June 09-10, 2016, Dallas, USA; 2nd International Conference and Expo on Drug Discovery and Designing, October 24-26, 2016, Istanbul, Turkey ; Asia Pacific Drug Formulation and Bioavailability Congress ,  Beijing, China, June 06-08, 2016; 6th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; EGA Pharmacovigilance Conference; Pharmacovigilance conferences and Clinical Trials; Conference on Pharmacovigilance and Drug Safety

Track 3: Pharmacovigilance Significance&Scope:

The focus in the track named Pharmacovigilance and its Significance and Scope will be on importance of pharmacovigilance. It will help to analyze its  potential as a major discipline within medical science, and to find out its influence on patient health and public welfare. This will help to better understand what is pharmacovigilance. In  Pharmacovigilance Practice we will come to know about Pharmacovigilance legislation, the rules and laws to follow. Pharma Industries have a major role in the improvement of Pharmacovigilance system to maintain the safety data.  Pharmacovigilance Conferences also deals with  Ecopharmacovigilance (EPV), pharmacoenvironmentology and pharmacovigilance in herbal medicines.

Related Conferences:

International Conference and Exhibition on Advances in HPLC and Chromatography Techniques , March 17-18, 2016, London, UK ; Asia Pacific Drug Formulation and  Bioavailability Congress, June 06-08, 2016, Beijing, China; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics , June 09-10, 2016,Dallas,USA; 6thInternational Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR,  September 12-14, 2016, San Atonio, USA ; 2nd International Conference and Expo on Drug Discovery and Designing, October 24-26, 2016, Istanbul, Turkey ; 6th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; EGA Pharmacovigilance Conference ; Conference on Pharmacovigilance and Drug Safety ; Pharmacovigilance Conferences and Clinical Trials

Track 4: Continental Pharmacovigilance:

Continental Pharmacovigilance provides a scope  to ensure compliance with local and international requirements, to operate more efficiently across various regions and health authorities.

Related Conferences:

International Conference and Exhibition on Advances in HPLC and Chromatography Techniques , March 17-18, 2016, London, UK ; Asia Pacific Drug Formulation and  Bioavailability Congress, June 06-08, 2016, Beijing, China; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics , June 09-10, 2016,Dallas,USA; 6thInternational Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR,  September 12-14, 2016, San Atonio, USA ; 2nd International Conference and Expo on Drug Discovery and Designing, October 24-26, 2016, Istanbul, Turkey ; 6th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; EGA Pharmacovigilance Conference ; Conference on Pharmacovigilance and Drug Safety ; Conference on Pharmacovigilance and Clinical Trials

Track 5: Good Pharmacovigilance Practice:

Pharmacovigilance and Pharmacoepidemiology role in the  risk management mainly focusses on  to overcome  insufficient evidence of safety from clinical trials. Good Pharmacovigilance  Practice avoids major problems in risk management which are discussed in Pharmacovigilance Conferences. It is of high importance to focus  on Signal investigation via observational studies and Interpreting safety signals. Concentrating on dosages forms in random clinical trials is very important. The Pharmacovigilance clinical trials service providing companies should have the Pharmacovigilance certification .

Related Conferences:

International Conference and Exhibition on Advances in HPLC and Chromatography Techniques , March 17-18, 2016, London, UK ; Asia Pacific Drug Formulation and  Bioavailability Congress, June 06-08, 2016, Beijing, China; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics , June 09-10, 2016,Dallas,USA; 6thInternational Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR,  September 12-14, 2016, San Atonio, USA ; 2nd International Conference and Expo on Drug Discovery and Designing, October 24-26, 2016, Istanbul, Turkey ; 6th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; EGA Pharmacovigilance Conference ; Conference on Pharmacovigilance and Drug Safety ; Conference on Pharmacovigilance and Clinical Trials

Track-6: Pharmacovigilance and Risk Management:

Pharmacovigilance and Risk Management play a major role in Drug Industry. The new turn in Drug Industry is to use Information technology in pharmacovigilance companies. Drug industry needs to promote companies in pharmacovigilance Practice and the Review of Softwares used in Pharmacovigilance and Clinical Trials. Monitoring of  unlicensed, off labels and orphan drugs is major task in risk management. In this conferences so many experts from different Pharmacovigilance CRO's ,pharmacovigilance service providers are participating to shares their knowledge and discuss about the new updates. In 2016  there is a Pharmacovigilance Conference , which is going to be held in Dubai, on April 28-29.

Related Conferences:

International Conference and Exhibition on Advances in HPLC and Chromatography Techniques ,March 17-18, 2016, London, UK; Asia Pacific Drug Formulation & Bioavailability Congress, Beijing, China, June 06-08, 2016; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics , June 09-10, 2016, Dallas, USA ; 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 12-14, 2016, San Atonio, USA;2nd International Conference and Expo on Drug Discovery and Designing, October 24-26, 2016, Istanbul, Turkey; 6th Annual Pharmacovigilance and Risk Management Strategies Forum; SCT 37th Annual Meeting (2016); Conference on Pharmacology and Toxicology Research; Pharmacovigilance Conferences and Risk Management Strategies 2016

Track-7: Pharmacokinetics and Pharmacodynamics:

Drugs at various steps undergo, Pharmacokinetics and Pharmacodynamics and toxicity testing through animal testing. These tests allow researchers to allometrically find out a safe starting dose of the drug for clinical trials in humans. This track will be  revolving around  Advances in Pharmacodynamic Interactions, Drug and substance abuse, Drug-drug interactions. Also discussion will be about the Pharmacy Practices to maintain the Pharmacokinetics and Pharmacodynamics, its Challenges and its guidelines. There are several challenges in compounding and dispensing practice in Pharmacokinetics and Pharmacodynamics which are also covered in Pharmacovigilance Conferences

Related Conferences:

Asia Pacific Drug Formulation and Bioavailability Congress , June 06-08, 2016, Beijing, China; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics , June 09-10, 2016, Dallas, USA;  2nd International Conference on Clinical Trials , August 22-24, 2016, Philadelphia, USA; 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 12-14, 2016, San Atonio, USA; 2nd International Conference and Expo on Drug Discovery and Designing, October 24-26, 2016, Istanbul, Turkey ;6th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; EGA Pharmacovigilance Conference; Pharmacovigilance Conferences and Drug Safety; Conference on Pharmacovigilance and Clinical Trials

Track 8: Pre-Clinical and Clinical Trials:

The main goals of Pre-Clinical and Clinical Trials are to determine the safe dose and start to assess product's safety profile. In Designing of trials there are pre-clinical studies and different phases of clinical trials. In this trails they estimate the Bioassay and its types. The Data collection and quality control is the major part in Pre-Clinical and Clinical Trials. For some specific drugs there are some Alternative trials designs and models are used. Pre-Clinical and Clinical Trials are conducted as Multi center trials and monitoring basis. Each Pre-Clinical and Clinical Trials study of a drug, biological product, or medical device regulated by the FDA must be reviewed, approved, and monitored by the Regulatory authorities and ethics committee. There are several types of clinical trials like Clinical trials on drugs used in respiratory disorders. Advanced Information technology in clinical trials improves the quality of Pre-Clinical and Clinical Trials which are a part of Pharmacovigilance Conferences

Related Conferences:

8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems , June 06-08, 2016, Beijing, China; Asia Pacific Drug Formulation & Bioavailability Congress, June 06-08, 2016, Beijing, China; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics , June 09-10, 2016, Dallas, USA; Anatomy and Physiology-2016, August 11-13, 2016, Birmingham, UK ; 2nd International Conference and Expo on Drug Discovery & Designing, October 24-26, 2016, Istanbul, Turkey; Outsourcing in Clinical Trials Europe 2016; 5th Annual Clinical Development and Trials Asia Congress; SCT 37th Annual Meeting (2016); Outsourcing in Clinical Trials East Coast 2016; Pharmacovigilance Conferences and Clinical Trials

Track-9: Clinical Trials on Various Disorders:

Clinical Trials on Drugs used in Various Disorders, Pharmacotherapy and Pharmacotherapeutics Emerging technology in clinical trials track mainly deals on the clinical trials in long chronic diseases and several disorders. In This track we will be discussing about the Recent clinical trials on AIDS, Clinical trials on benign and malignant tumours, Clinical trials on cardiovascular diseases, Clinical trials on diabetes, Clinical trials of monoclonal and polyclonal antibodies, Clinical trials on drugs used in psychological disorders The current research mainly focuses on Applications of biomarkers in clinical trials. These are a part of Pharmacovigilance Conferences

Related Conferences:

8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems , June 06-08, 2016, Beijing, China; Asia Pacific Drug Formulation & Bioavailability Congress, June 06-08, 2016, Beijing, China; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics , June 09-10, 2016, Dallas, USA; Anatomy and Physiology-2016, August 11-13, 2016, Birmingham, UK ; 2nd International Conference and Expo on Drug Discovery & Designing, October 24-26, 2016, Istanbul, Turkey; Outsourcing in Clinical Trials Europe 2016; 5th Annual Clinical Development and Trials Asia Congress; SCT 37th Annual Meeting (2016); Outsourcing in Clinical Trials East Coast 2016; Pharmacovigilance Conferences and Clinical Trials

Track-10: Clinical Research and Statistics:

In Clinical Research Statistics plays major role. Depends upon the Statistics the clinical trials go for regulatory submissions. There are several guidelines mainly ICH guidelines for clinical research and its statistics follow for the clinical research. Stastical analysis of past pharmacovigilance conferences and adverse drug reactions reports also consider for the regulatory submission.

Related Conferences:

8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, March 07-09, 2016, Madrid, Spain; International Conference and Exhibition on Advances in HPLC and Chromatography Techniques , March 17-18, 2016, London, UK; International Conference and Exhibition on Medical Writing and Healthcare Communications, April 28-29, 2016, Dubai, UAE; 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 12-14, 2016, San Atonio, USA; International Conference on Precision Medicine, November 03-05, 2016, Baltimore, USA; Conference on Pharmacodynamics, Biomarkers and Personalised Therapy; Conference on Drug Formulation, Bioavailability and Pharmacy; Conference on Drug Formulation, Bioavailability and Pharmacological Sciences; Conference on Developing Countries and Pharmacological Sciences; Conference on Pharmacology and Toxicology Research

Track-11: Case Report in Clinical Trials:

Case Report in Clinical Trials plays major role in clinical research. In this track focus will be  about the several case reports like Cancer case reports, Cardiovascular trials case report, Case studies on sexually transmitted diseases, Case studies on type 1 and type 2 diabetes, Case reports on drugs used in pregnancy and lactation.

Related Conferences:

8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, March 07-09, 2016, Madrid, Spain; International Conference and Exhibition on Advances in HPLC and Chromatography Techniques , March 17-18, 2016, London, UK; International Conference and Exhibition on Medical Writing and Healthcare Communications, April 28-29, 2016, Dubai, UAE; 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 12-14, 2016, San Atonio, USA; International Conference on Precision Medicine, November 03-05, 2016, Baltimore, USA; Conference on Pharmacodynamics, Biomarkers and Personalised Therapy; Conference on Drug Formulation, Bioavailability and Pharmacy; Conference on Drug Formulation, Bioavailability and Pharmacological Sciences; Conference on Developing Countries and Pharmacological Sciences; Conference on Pharmacology and Toxicology Research

Track-12: Biopharmaceutics:

In Clinical Pharmacology and Bio pharmaceutics track discussion will be about the Rational drug management of cancer, diabetes and cardiovascular disorders, and Management of psychiatric disorders and autoimmune disorders. Along with clinical trials Bioavailability and bioequivalence studies also plays major role in clinical research.

Related Conferences:

8th International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems, March 07-09, 2016, Madrid, Spain; International Conference and Exhibition on Advances in HPLC and Chromatography Techniques, March 17-18, 2016, London, UK; Asia Pacific Drug Formulation and  Bioavailability Congress, June 06-08, 2016, Beijing, China; 7th World Congress on Bioavailability and  Bioequivalence: BA/BE Studies Summit, August 29-31, 2016, Atlanta, USA; 5th Biologics and Biosimilars Conference, September 12-14, 2016, San Antonio, USA; Conference on Biomedical and Pharmaceutical Sciences; Conference on Drug Formulation, Bioavailability and Pharmacological Sciences; Conference on Biopharmaceutics and Drug Delivery Systems; Conference on Biopharmaceutics and Pharmacodynamics; Conference on Biopharmaceutical and Life Sciences

Track-13: PV Data Base Management:

There is advantage in centralising all safety data, clinical data, analysis and reporting with one provider. Pharmacovigilance Software tool provides comprehensive analysis of adverse events arising from the use of pharmaceutical products (Medicinal Product, Medical Device, Vaccines, Non-Drug Therapy and Veterinary Medicinal Product). The drug safety database allows the risk- benefit analysis of medicinal products taking into account new and emerging information, in the context of cumulative information. Pharmacovigilance since beginning has been a compliance driven activity, wherein your regulatory compliance determines company’s risk assessment scores. A drug safety database offers scheduling of alerts for expedited cases, follow-up cases and PSUR/PADER reports submission to meet regulatory timeline compliance. PV database is also covered in Pharmacovigilance Conferences

Related Conferences:

International Conference and Exhibition on Advances in HPLC and Chromatography Techniques , March 17-18, 2016, London, UK ; Asia Pacific Drug Formulation and  Bioavailability Congress, June 06-08, 2016, Beijing, China; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics , June 09-10, 2016,Dallas,USA; 6thInternational Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR,  September 12-14, 2016, San Atonio, USA ; 2nd International Conference and Expo on Drug Discovery and Designing, October 24-26, 2016, Istanbul, Turkey ; 6th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; EGA Pharmacovigilance Conference ; Conference on Pharmacovigilance and Drug Safety ; Pharmacovigilance Conferences and Clinical Trials

Track-14: PV Consulting’s and Business opportunity:

Due to the changing resources necessary to fulfil the regulatory requirements, some companies also choose to outsource or out task regulatory affairs to external service providers. Regulatory Affairs department is constantly evolving and growing and is the one which is least impacted during the Acquisition and Merger, and also during recession. The stringent regulations on safety monitoring and their periodical revision have led to increased safety data collection, analysis and regulatory surveillance, and increased costs. Thus, Pharmacovigilance has become a critical phase in clinical development programs.

Related Conferences:

International Conference and Exhibition on Advances in HPLC and Chromatography Techniques , March 17-18, 2016, London, UK ; Asia Pacific Drug Formulation and  Bioavailability Congress, June 06-08, 2016, Beijing, China; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics , June 09-10, 2016,Dallas,USA; 6thInternational Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR,  September 12-14, 2016, San Atonio, USA ; 2nd International Conference and Expo on Drug Discovery and Designing, October 24-26, 2016, Istanbul, Turkey ; 6th Annual Pharmacovigilance and Risk Management Strategies Forum; Pharmacovigilance and Risk Management Strategies 2016; EGA Pharmacovigilance Conference ; Conference on Pharmacovigilance and Drug Safety ; Pharmacovigilance Conferences and Clinical Trials

Track-15: Regulatory affairs:

Regulatory affairs for clinical trials is the major part in the clinical trials approaches. Every clinical trial must be conduct according to the Regulatory affairs guidelines. There are several Regulatory affairs depending upon the countries. Regulatory Affairs departments are growing within companies. Global harmonization in standards has led to consistent approach in regulatory submissions and hence its review.


Related Conferences:

International Conference and Exhibition on Advances in HPLC and Chromatography Techniques , March 17-18, 2016, London, UK ; Asia Pacific Drug Formulation & Bioavailability Congress, June 06-08, 2016, Beijing, China; 2ndInternational Conference on Therapeutic Drug Monitoring and Toxicogenomics , June 09-10, 2016, Dallas, USA; 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 12-14, 2016, San Atonio, USA; 2nd International Conference and Expo on Drug Discovery and Designing, October 24-26, 2016, Istanbul, Turkey ; 6th Annual Pharmacovigilance and Risk Management Strategies Forum; SCT 37th Annual Meeting (2016); Conference on Pharmacology and Toxicology Research; Pharmacovigilance and Risk Management Strategies 2016

Track-16: Growth strategies in Pharma:

Strategies for Growth in Pharma Environment track mainly focused in Strategic development towards FDA approval and Post market product surveillances. The updates and advances in pharmacovigilance regulation system will be discussed in Advances in changing pharmacovigilance regulation system track. These strategies are covered in the Pharmacovigilance Conferences

Related Conferences:

8th International Conference and Exhibition on Pharmaceutics and  Novel Drug Delivery Systems  , March 07-09, 2016, Madrid, Spain; International Conferences and Expo on Industrial Pharmacy, April 28-29, 2016, Dubai, UAE;  6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, , September 12-14, 2016, San Atonio, USA; Conference on Pharmacy and Pharmaceutical Sciences; Conference on Pharmaceutical Analysis; Conference on Pharmacy and Pharmacological Sciences; 6th Annual Pharmacovigilance and Risk Management Strategies Forum; SCT 37th Annual Meeting (2016)

Track-17: Pharmacy Practices and its Challenges:

In Pharmacy Practices and its Challenges track mainly focused on Pharmacy practice and its guidelines and Challenges in compounding and dispensing practice. Dosage regimen, drug toxicity and drug safety measures place important position in clinical research.

Related Conferences:

8th International Conference and Exhibition on Pharmaceutics and  Novel Drug Delivery Systems  , March 07-09, 2016, Madrid, Spain; International Conferences and Expo on Industrial Pharmacy, April 28-29, 2016, Dubai, UAE; World Drug Delivery Summit, June 30-July 02, 2016, New Orleans, USA; 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR, September 12-14, 2016, San Atonio, USA; International Conference on Pharma Marketing, November 17-19, 2016, Alicante, Spain; Conference on Pharmacy and Pharmaceutical Sciences; Conference on Pharmaceutical Analysis; Conference on Pharmacy and Pharmacological Sciences; 6th Annual Pharmacovigilance and Risk Management Strategies Forum; SCT 37th Annual Meeting (2016)

Conference Series LLC organizing splendorous Pharmaceutical conferences welcomes you to attend the 5th Global Pharmacovigilance Summit to be held during April 28-29, 2016 in Dubai UAE, focuses on the advancements in pharmacovigilance and risk management. The field of Pharmacovigilance is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals.
 
5th Global Pharmacovigilance Summit emphasizes on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors. Main theme of 5th Global Pharmacovigilance Summit is “Ensure Safer Drugs to the Healthcare Community”
 
 

Why to attend???

With members from around the world focused on learning about Pharmacovigilance and its advances; this is your best opportunity to reach the largest assemblage of participants from the Pharmacovigilance community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Pharmacovigilance are hallmarks of this conference.

Target Audience:

  • Pharmacovigilance Students, Scientists
  • Pharmacovigilance Researchers
  • Pharmacovigilance Faculty
  • Medical Colleges
  • Pharmacovigilance Associations and Societies
  • Business Entrepreneurs
  • Training Institutes
  • Software developing companies
  • Manufacturing Medical Devices Companies
  • Data Management Companies

Summary: Global Pharmacovigilance 2016 welcomes attendees, presenters, and exhibitors from all over the world to Dubai, UAE. We are delighted to invite you all to attend and register for the “5th Global Pharmacovigilance Summit” which is going to be held during April 28-29, 2016 at Dubai, UAE. The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Global Pharmacovigilance 2016, where you will be sure to have a meaningful experience with scholars from around the world. All the members of Global Pharmacovigilance 2016 organizing committee look forward to meet you at Dubai, UAE.

 

Importance and Scope: Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem.The main purpose of pharmacovigilance is to improve the patient's safety and enhance his care in terms of the use of medicines, including paramedical interventions.Pharmacovigilance also supports public health programs by providing reliable information for the efficient assessment of the risk-benefit profile of medicines. Contribute to the assessment of benefits, uses, side effects, harm, effectiveness and risk of medicines.Encouraging the safe, rational and more effective (including cost-effective) use of various medicines.Promote education, understanding and clinical training in pharmacovigilance and its effective availability to the public.

Why Dubai, UAE?

The Pharma Industry is responsible for the development, production and marketing of medications. According to IMS Health Consulting, an international research company, in 2012 the size of the global pharmaceutical market reached $940 billion. In monetary terms it grew by 6%. In the future the sector is expected to grow at no less than 3% to 4% a year and if this happens the global pharmaceutical market is expected to reach $1.1 trillion by 2015 and will reach $1.2 trillion in 2016 and up to $1.5 trillion by 2020. The global demographic, epidemiological and economic changes are transforming the pharmaceutical market. The world population is growing rapidly and is projected to rise from 7 billion in 2011 to 7.7 billion in 2020 and 9.6 billion in 2050, hence an increase in the demand for pharmaceuticals. The global pharmaceuticals market is worth US$300 billion a year, a figure expected to rise to US$400 billion within three years. Economically, the Middle East (ME) is well positioned to be the one of next growth engine of global pharmaceutical business: several countries in the region enjoy robust economic growth and the highest cash reserves per capita in the world. The pharmaceutical Industry is consequently flourishing as the expanding middle class demands better care, and government healthcare spending continues to grow. The pharmaceutical market in the Middle East is likely to grow by between ten and 15 percent annually over the next three years, outstripping more mature markets, forecasts a report from URCH Publishing. The Middle East pharma markets are showing consistent growth over the last years in particular in the area of specialized medication. The market for pharmaceutical products is still expected to grow in many countries across the region.

 

Welcome Message

 

Conference Highlights

  • Drug Safety
  • Adverse Drug Reactions
  • Pharmacovigilance Significance &Scope
  • Continental Pharmacovigilance
  • Good Pharmacovigilance Practice
  • Pharmacovigilance and Risk Management
  • Pharmacokinetics and Pharmacodynamics
  • Pre-Clinical and Clinical Trials
  • Clinical Trials on Various Disorders
  • Clinical Research and Statistics
  • Case Report in Clinical Trials
  • Biopharmaceutics
  • PV Data Base Managemaent
  • PV Consultings And Bussiness opportunity
  • Regulatory affairs
  • Growth strategies in Pharma
  • Pharmacy Practices and its Challenges

 

 

The Middle East pharma market was valued at $14.8bn in 2008, registering a y-o-y sales growth of 12.6%, and is forecast to return at a CAGR of 8.1% between 2008 and 2014 to reach a total value of 23.5bn by the end of 2014. The general anti-infective market is expected to generate the highest sales of $3.9bn by the end of 2014, followed by alimentary canal & metabolic disorders at $3.7bn.
General anti-infectives, alimentary canal & metabolism and cardiovascular disorders remained as top selling therapeutic categories in the Middle East, while registering 2008 sales of $2.6bn, $2.3bn and $1.9bn respectively.
The leading brands in the Middle East pharmaceutical market had a predominance of respiratory and cardiovascular drugs. However, the top 10 brands constituted a very small fraction of the Middle East market, with other drugs making up 94.1% of the total market in 2008. GSK's asthma and COPD drug Seretide dominated the market with 2008 sales of $134m, a strong growth of 21% over 2007.
 

 

Welcome Message

 

Market of Spending on medicines
 
Past spending growth offers few clues to the level of growth to expect through 2015 – Unprecedented dynamics are at play — including historically high levels of patent expiry, rapid expansion of demand for medicines in the world's fastest growing economies, fewer new medicines reaching patients, and more moderate uptake of those that do become available – These dynamics are driving rapid shifts in the mix of spending between branded products and generics; and between spending in the major developed countries and those 17 high growth emerging countries referred to as 'pharmerging‘.
 

 

Welcome Message

 

Global Pharma Market Growth
 
According to IMS Health Consulting, an international research company, in 2012 the size of the global pharmaceutical market reached $940 billion. In monetary terms it grew by 6%. In the future the sector is expected to grow at no less than 3% to 4% a year and if this happens the global pharmaceutical market is expected to reach $1.1 trillion by 2015 and will reach $1.2 trillion in 2016 and up to $1.5 trillion by 2020. The global demographic, epidemiological and economic changes are transforming the pharmaceutical market. The world population is growing rapidly and is projected to rise from 7 billion in 2011 to 7.7 billion in 2020 and 9.6 billion in 2050, hence an increase in the demand for pharmaceuticals.
 
The ageing process also affects the demand. By 2020 about 9.4% of the world population (719.4 million people) will be 65 or above, compared with 7.3% (477.4 million) in 2005 (UN, 2013). Clinical advances reinforce this trend. The improvements of the past few decades have already converted some previously terminal illnesses into chronic conditions, thus increasing long-term demand for therapies to manage these diseases. Older people consume more medicines than younger people: four in five of those aged over 75 take at least one prescription product, while 36% take four or more. Therefore, the population age structure makes it possible to forecast an increase in the demand for medicines in this age group. Many producers of original medicines will have their patents expire very shortly. This “patent cliff” and the mass production of generics will cause a significant reduction in prices as a result of which the income of the pharmaceutical market will decrease by $148 billion between 2012 and 2018.
 
Spending on medicines will reach nearly $1,100Bn in 2015, reflecting a slowing growth rate of 3-6% over the five year period compared to 6.2% annual growth over the past five years. Absolute global spending growth is expected to be $210-240Bn, compared to $251Bn since m2005.The U.S. share of global spending will decline from 41% in 2005 to 31% in 2015, while the share of spending from the top 5 European countries will decline from 20% to 13% over the same period. Meanwhile, 17 high growth emerging markets led by China, will contribute 28% of total spending by 2015, up from only 12% in 2005.The next five years will also see an accelerating shift in spending toward generics, rising to 39% of spending in 2015, up from 20% in 2005.
 

 

Welcome Message

 

  • Growth in the next five years will slow to3-6% CAGR compared to 6.2% over the past five years.
  • Spending on medicines globally is expected to exceed $1 trillion dollars in2014 and to reach nearly $1,100Bn by 2015.
  • Absolute growth is expected to be $210-240Bn compared to $251Bn in the prior five years.
  • Removing the effect of exchange rate fluctuations, growth will be $230-250Bn on a constant dollar basis, compared to $228Bn in the previous five years.
Middle East Pharma Market Growth
 
The pharmaceutical market in the Middle East is likely to grow by between ten and 15 percent annually over the next three years, outstripping more mature markets, forecasts a report from URCH Publishing.
 
Major Pharmaceutical Markets of the Middle East (2nd Ed): An overview of Egypt, Israel, Jordan, Lebanon, Saudi Arabia & UAE, says that massive growth is being forecast for the pharmaceutical and biotechnology markets of Middle Eastern states, driven by moves to liberalise national economies, the introduction of mass health insurance and the determination of the region's governments to become self-sufficient in pharmaceuticals production.
 
All these factors are leading to huge investments taking place in both the private and public health sectors, with major benefits to the pharmaceutical industry.

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date April 28-29, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2
Poster Opportunity Closed Click Here to View

Media Partners